Literature DB >> 4026886

The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus.

R M Valentijn, H van Overhagen, H M Hazevoet, J Hermans, A Cats, M R Daha, L A van ES.   

Abstract

Serial serum samples from 33 patients with systemic lupus erythematosus were tested for CH50, C3, C4, and circulating immune complexes. Circulating immune complexes were determined by 5 different assays. Disease activity was determined by a scoring system we devised. On an interpatient analysis, overall disease activity correlated significantly with levels of CH50, C3, and a positive result on C1q binding assay. However, with the exception of depressed C3 levels, the sensitivity, specificity, and predictive values of all the serologic tests were low. An intrapatient analysis revealed a patient-specific activity parameter in 11 of the 33 patients. We conclude that these serologic tests are not reliable in assessing disease activity in patients with systemic lupus erythematosus, although a small subgroup of patients will exhibit a patient-specific activity parameter.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026886     DOI: 10.1002/art.1780280810

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  44 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 2.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

3.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

Review 4.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

5.  Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis.

Authors:  Nirmal K Banda; Gaurav Mehta; Viviana P Ferreira; Claudio Cortes; Matthew C Pickering; Michael K Pangburn; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2013-02-22       Impact factor: 5.422

6.  Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.

Authors:  G Senaldi; V A Makinde; D Vergani; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

7.  C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus.

Authors:  G Wild; J Watkins; A M Ward; P Hughes; A Hume; N R Rowell
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

8.  Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis.

Authors:  M L Westedt; M R Daha; W M Baldwin; T Stijnen; A Cats
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

Review 9.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

10.  Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.

Authors:  E Röther; B Lang; R Coldewey; K Hartung; H H Peter
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.